[
  {
    "ts": null,
    "headline": "Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)",
    "summary": "WILMINGTON, Del., September 24, 2025--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)",
    "url": "https://finnhub.io/api/news?id=6d02f7e68035b8627290ec6cf44641f2958e90c588970f69d82ec39c6df39705",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758745800,
      "headline": "Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)",
      "id": 136866413,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., September 24, 2025--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)",
      "url": "https://finnhub.io/api/news?id=6d02f7e68035b8627290ec6cf44641f2958e90c588970f69d82ec39c6df39705"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Softer Wednesday Afternoon",
    "summary": "Health care stocks were lower Wednesday afternoon, with the NYSE Health Care Index shedding 0.2% and",
    "url": "https://finnhub.io/api/news?id=624864140ffde08c3d2f0b51651d5a3d83f9cde106e7b4be766b1856cf9ef982",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758736466,
      "headline": "Sector Update: Health Care Stocks Softer Wednesday Afternoon",
      "id": 136866414,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Health care stocks were lower Wednesday afternoon, with the NYSE Health Care Index shedding 0.2% and",
      "url": "https://finnhub.io/api/news?id=624864140ffde08c3d2f0b51651d5a3d83f9cde106e7b4be766b1856cf9ef982"
    }
  },
  {
    "ts": null,
    "headline": "Incyte’s Povorcitinib Shows Sustained Efficacy in Phase 3 HS Trial, Supports 2025/2026 Regulatory Submissions",
    "summary": "Incyte Corporation (NASDAQ:INCY) is one of the best innovative stocks to buy now. On September 17, Incyte announced new 24-week interim data from its pivotal Phase 3 STOP-HS clinical trial program for povorcitinib/INCB54707, which is an oral small-molecule, highly-selective JAK1 inhibitor, in adult patients with moderate to severe hidradenitis suppurativa/HS. The results support the company’s planned […]",
    "url": "https://finnhub.io/api/news?id=9fd164be453ad03d2a801468f441e0f64392c192ec38f048798c018df881316b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758693482,
      "headline": "Incyte’s Povorcitinib Shows Sustained Efficacy in Phase 3 HS Trial, Supports 2025/2026 Regulatory Submissions",
      "id": 136862200,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte Corporation (NASDAQ:INCY) is one of the best innovative stocks to buy now. On September 17, Incyte announced new 24-week interim data from its pivotal Phase 3 STOP-HS clinical trial program for povorcitinib/INCB54707, which is an oral small-molecule, highly-selective JAK1 inhibitor, in adult patients with moderate to severe hidradenitis suppurativa/HS. The results support the company’s planned […]",
      "url": "https://finnhub.io/api/news?id=9fd164be453ad03d2a801468f441e0f64392c192ec38f048798c018df881316b"
    }
  }
]